18 Citations (Scopus)


We show that TAP/Sec14L2 had a high expression in normal/benign breast, prostate, and liver tissues as compared to lung, colon, and kidney. Its expression was downregulated in breast cancer cell lines shown by quantitative-PCR. Further, 57% of 141 human invasive breast carcinomas had no or markedly reduced TAP/Sec14L2 expression by immunohistochemical staining, and the rate increased to 80% in high grade invasive carcinomas ( p <.01). This downregulation of TAP/Sec14L2 was also present in ductal carcinoma in situ(DCIS) associated with invasive carcinomas. These findings raise the possibility that TAP/Sec14L2 may serve as a tumor suppressor in breast carcinogenesis.

Original languageEnglish
Pages (from-to)971-977
Number of pages7
JournalCancer Investigation
Issue number10
Publication statusPublished - Nov 13 2009


  • BCa
  • TAP

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer'. Together they form a unique fingerprint.

Cite this